

New COVID-19 Vaccine Codes: August Update

CPT® Assistant.

August 2023 Special Edition

Note:

In the CPT® Assistant Special Edition for August 2023 (see page 3), two of the new codes' (91318, 91319) volume dosages were incorrectly listed as 3 mcg/0.2 mL (91318) and 10 mcg/0.2 mL (91319) respectively.

The correct volume dosages are as follows:

#91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

(Report 91318 with administration code 90480)

#91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

(Report 91319 with administration code 90480)

Based on recent recommendations made by the Food and Drug Administration (FDA) to shift to a monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) vaccine that targets the predominant XBB lineage virus strain for the 2023-2024



vaccine administration season, the Current Procedural Terminology (CPT®) Editorial Panel (the Panel) has approved new monovalent COVID-19 vaccine product codes for Pfizer and Moderna vaccines. Codes 91318, 91319, 91320 were approved for the new monovalent vaccine products from Pfizer, and codes 91321 and 91322 were approved for the new monovalent vaccine products from Moderna. In addition, a new vaccine administration code (90480) was approved for reporting the administration of any COVID-19 vaccine for any patient (pediatric or adult), replacing all previously approved specific vaccine administration codes. The new vaccine product codes will become effective upon receiving approval from the FDA.

All previously approved COVID-19 vaccine product and vaccine administration codes will be deleted from the CPT® code set effective November 1, 2023. The exception will be vaccine product code 91304, which represents the Novavax COVID-19 vaccine product, which will remain active.


Lastly, given that the COVID-19 vaccine product and vaccine administration codes have been streamlined, Appendix Q will also be deleted from the CPT® code set effective November 1, 2023.

To assist CPT® code users in differentiating and reporting the available vaccine product codes and the associated immunization administration codes appropriately, the American Medical Association (AMA) established a website (<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>) that features timely updates of the Panel's actions. The last COVID-19 update was in the CPT® Assistant Special Edition: May Update (2023) in which new vaccine administration codes for the Pfizer and Moderna bivalent vaccines were discussed.

This issue of CPT® Assistant Special Edition provides guidance on the appropriate use of the new Pfizer and Moderna monovalent vaccine product codes with the new vaccine administration code based on these recent COVID-19 vaccine recommendations.

product codes will become effective upon receiving approval from the FDA.

Immunization Administration for Vaccines/Toxoids

#90480 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose

☒(Report 90480 for the administration of vaccine 91304, 91318, 91319, 91320, 91321, 91322)☒

☒(Do not report 90480 in conjunction with non-COVID 90476-90759 vaccines, toxoids)☒

Vaccines, Toxoids

#☒91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use

☒(Report 91304 with administration code 90480)☒

#☒☒91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

☒(Report 91318 with administration code 90480)☒

#☒☒91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use

☒(Report 91319 with administration code 90480)☒

#☒☒91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

☒(Report 91320 with administration code 90480)☒

#☒☒91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use

☒(Report 91321 with administration code 90480)☒

#☒☒91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use

☒(Report 91322 with administration code 90480)☒

Recently, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), an advisory group of the FDA, met to discuss which strain(s) of the COVID-19 virus should be included in a vaccine for the 2023-2024 vaccination season. The VRBPAC recommended that the COVID-19 vaccine for the 2023-2024 vaccination season be a monovalent vaccine that contains the XBB.1.5 strain. Pfizer and Moderna are currently updating their vaccine products to reflect this change.

Given the recommendation from the VRBPAC, which indicates switching COVID-19 vaccinations to annual updates (similar to influenza vaccinations) and the expiration of the public health emergency (PHE) in May 2023, there is no longer a need for the coding granularity of individual administration codes for every vaccine product. This makes it possible to revise the CPT® COVID-19 vaccine product and vaccine administration code structure to align with the existing CPT vaccine product and vaccine administration codes. This alignment effort contains several parts. The first part is the approval of three new vaccine product codes for the Pfizer COVID-19 products and two new vaccine product codes for the Moderna COVID-19 products. The codes and their descriptors and associated age ranges are listed in Table 1 (Pfizer) and Table 2 (Moderna).

Table 1. New Pfizer Vaccine Product Codes & Age Ranges

Code	Descriptor	Age Range
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	6 months through 4 years

91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	5 years through 11 years
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	12 years and older

Table 2. New Moderna Vaccine Product Codes & Age Ranges

Code	Descriptor	Age Range
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	6 months through 11 years
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	12 years and older

The second part of the alignment process is the approval of a single COVID-19 vaccine administration code (90480) to be used with **all** COVID-19 vaccine product codes. As with previous, more granular COVID-19 vaccine administration codes, counseling is included in code 90480 and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the Centers for Disease Control and Prevention (CDC) regarding which patients should receive a COVID-19 vaccine is available at

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html>.

Because all other previously approved COVID-19 vaccine products, except for the Novavax product (91304), will no longer be recommended for use, the third part of the alignment process involves deleting all other previously approved CPT® COVID-19 vaccine product and vaccine administration codes. The codes that will be deleted effective November 1, 2023 are listed below in Table 3.

Vaccine Code	Vaccine Administration Code(s)	Age Range	Manufacturer
91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	0001A (1st Dose) 0002A (2nd Dose) 0003A (3rd Dose) 0004A (Booster)	12 years and older	Pfizer, Inc
91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0051A (1st Dose) 0052A (2nd Dose) 0053A (3rd Dose) 0054A (Booster)	12 years and older	Pfizer, Inc



91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0121A (1st Dose) 0124A (Additional Dose)	12 years and older	Pfizer, Inc
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0071A (1st Dose) 0072A (2nd Dose) 0073A (3rd Dose) 0074A (Booster)	5 through 11 years	Pfizer, Inc
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0151A (1st Dose) 0154A (Additional Dose)	5 through 11 years	Pfizer, Inc



91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0081A (1st Dose) 0082A (2nd Dose) 0083A (3rd Dose)	6 months through 4 years	Pfizer, Inc
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0171A (1st Dose) 0172A (2nd Dose) 0173A (3rd Dose) 0174A (Additional Dose)	6 months through 4 years	Pfizer, Inc
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	0011A (1st Dose) 0012A (2nd Dose) 0013A (3rd Dose)	12 years and older	Moderna, Inc
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	0064A (Booster)	18 years and older	Moderna, Inc
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0134A (Additional Dose)	12 years and older	Moderna, Inc



91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0141A (1st Dose) 0142A (2nd Dose) 0144A (Additional Dose)	6 months through 11 years	Moderna, Inc
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0111A (1st Dose) 0112A (2nd Dose) 0113A (3rd Dose)	6 months through 5 years	Moderna, Inc
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	0164A (Additional Dose)	6 months through 5 years	Moderna, Inc
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0091A (1st Dose) 0092A (2nd Dose) 0093A (3rd Dose) 0094A (Booster)	6 years through 11 years 18 years and older	Moderna, Inc
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	0021A (1st Dose) 0022A (2nd Dose)	18 years and older	Astra Zeneca, Plc

91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	0031A (Single Dose) 0034A (Booster)	18 years and older	Janssen
N/A		0041A (1st Dose) 0042A (2nd Dose)	12 years and older	Novavax, Inc
		0044A (Booster)	18 years and older	
91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	0104A (Booster)	18 years and older	Sanofi Pasteur

Note that vaccine product code 91304, representing the Novavax vaccine product, is not being deleted (see Table 4). The Novavax COVID-19 vaccine continues to be available for use; however, the vaccine administration codes (0041A, 0042A, and 0044A) that were previously used for reporting its administration will be deleted but should continue to be used until code 90480 becomes effective, pending FDA approval of the new COVID-19 vaccines. Once code 90480 becomes effective, it should be used to report administration of the Novavax vaccine. As a result, the parenthetical note for code 91304 was revised to reflect this change.

Table 4: Retained COVID-19 Vaccine Product

Code	Descriptor	Age Range
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use	12 years and older

Given that most of the previously approved COVID-19 codes have been deleted and the new coding structure offers a more streamlined approach, Appendix Q will be deleted from the CPT® code set as well.

Note that because the decision to delete these codes took place after the CPT® 2024 codebook was finalized, these deleted codes and Appendix Q will be in the CPT® 2024 codebook. Because of this, it is important for CPT® code users to refer to the AMA website for the most up-to-date information. Additional details on the vaccine coding structure and other pertinent information provided in multiple Special Editions of the CPT® Assistant for COVID-19 guidance are available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Typical Patient (91304)

A 33-year-old individual seeks immunization against SARS-CoV-2 virus to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of the SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91304)

The physician or other QHP determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.



Typical Patient (91318)

A parent or guardian of a 1-year-old female seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (91318)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Typical Patient (91319)

A parent or guardian of a 7-year-old male seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (91319)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.



Typical Patient (91320)

A 33-year-old female seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91320)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Typical Patient (91321)

A parent or guardian of a 1-year-old male seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (91321)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Typical Patient (91322)

A 33-year-old female seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.



Description of Procedure (91322)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Typical Patient (90480)

A 65-year-old female presents for possible immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. After counseling, she is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (90480)

It is confirmed that vaccination to decrease the risk of COVID-19 is indicated. Counseling of the patient, parent, or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.